Provider Resources and Guidance

*Suspected or confirmed active tuberculosis disease is a reportable condition in Alaska.*

Cases should be reported to the Alaska TB Program within 2 business days. Please call the Section of Epidemiology at 907-269-8000, or complete the appropriate report form and fax to 907-561-4239.

Spotlight

Core Curriculum on Tuberculosis:
What the Clinician Should Know

Screening/Testing/Assessment

The USPSTF recommends screening for latent TB infection (LTBI) in populations at increased risk. Finding and treating patients with LTBI is key to controlling the TB epidemic.

Alaska Specific Guidance:

• Alaska TB Infection Risk Assessment form
• Alaska TB Disease Symptom Screening form
• TST Cutpoints for Alaska

IGRA (blood) testing is now approved for all persons>2 years of age and has some advantages over TST (skin test), especially in foreign-born persons who may have received BCG vaccination in the past.

• OAT/IDSA/CDC Clinical Practice Guidelines: Diagnosis of in Adults and Children
• Online TST/IGRA Interpreter (McGill University)
• BCG World Atlas

Tuberculosis Infection (TBI), also known as Latent TB Infection (LTBI)

• CDC: Latent Tuberculosis Infection Resources
  
• LTBI Guide for Primary Health Care Providers (CDC)
• NTCA LTBI Clinical Recommendations (2/5/2021)
• U.S. LTBI Recommendations Overview (CDC)

Active Tuberculosis Disease

• ATS/IDSA/CDC Tuberculosis Treatment Guidelines (2016)
• Curry International Tuberculosis Center – Drug Resistant Tuberculosis: A Survival Guide for Clinicians, 3rd edition/2022 Updates

Additional Resources